Immunotherapy of Crohn's disease

Scandinavian Journal of Immunology

Volumn 51, Issue 1, 2000, Pages 18-22

  Van Deventer, S J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO; RECOMBINANT INTERLEUKIN 10;

ANTIGEN PRESENTING CELL; APOPTOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CROHN DISEASE; HUMANS; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; INTERLEUKIN-10; NEUTRALIZATION TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033985372     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2000.00657.x     Document Type: Review

References (43)

1. 1 Hanauer SB, Meyers S. Management of Crohn's disease in adults [see comments]. Am J Gastroenterology 1997;92:559-66.
2. 2 Hanauer SB. Inflammatory bowel disease [published erratum appears in N Engl J Med. Jul, 1996;11:335 (2): 143] New England Journal of Medicine 1996;334:841-8.
3. 3 Munkholm P. Crohn's disease - occurrence, course and prognosis. An epidemiologic cohort-study. Danish Med Bulletin 1997;44:287-302.
4. 4 Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterology 1995;30:699-706.
5. 5 Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A Meta-Analysis Ann Intern Medicine 1995;123:132-42.
6. 6 Breese E, MacDonald TT. TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol 1995;371B:821-4.
7. 7 Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
8. 8 Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathology 1993;46:757-60.
9. 9 Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease [see comments]. Gut 1993;34: 1705-9.
10. 10 Van Deventer SJ. Tumour necrosis factor and Crohn's disease [see comments]. Gut 1997;40:443-8.
11. 11 McHugh SM, Rowland TL. Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunology 1997;110:151-4.
12. 12 Hashimoto Y. Novel biological response modifiers derived from thalidomide. Current Med Chemistry 1998;5:163-78.
13. 13 Reimund JM, Dumont S, Muller CD et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 1997;40:475-80.
14. 14 Levi M, Ten Cate H, Bauer KA et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Investigation 1994;93:114-20.
15. 15 Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986;232:977-80.
16. 16 Black RA, Rauch CT, Kozlosky CJ et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-33.
17. 17 Moss ML, Jin SL, Becherer JD et al. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 1997;72:127-9.
18. 18 Moss ML, Jin SL, Milla ME et al. Cloning a Disintegrin Metalloproteinase That Processes Precursor Tumour-Necrosis Factor-Alpha [Published Erratum Appears In Nature 1997;385:733-6.
19. 19 Odeka EB, Miller V. Thalidomide in oral Crohn's disease refractory to conventional medical treatment [letter; comment]. J Pediatric Gastroenterol Nutrition 1997;25:250-1.
20. 20 Wettstein AR, Meagher AP. Thalidomide in Crohn's disease [letter]. Lancet 1997;350:1445-6.
21. 21 Bauditz J, Rucken Y, Raedler A, Nikolaus S, Lochs H, Schreiber S. Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease [letter; comment]. Lancet 1995;345:1445.
22. 22 Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease [see comments]. Gut 1997;40:470-4.
23. 23 Van Dullemen HM, Van Deventer SJH, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
24. 24 Targan SR, Hanauer SB, Van Deventer SJ et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England J Med 337:1029-35.
25. 25 Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England J Med 1999;340:1398-405.
26. 26 Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease [see comments]. Lancet 1997;349:521-4.
27. 27 Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R. Treatment of Ulcerative Colitis in the Cottontop Tamarin Using Antibody to Tumour Necrosis Factor Alpha. Gut 1997;40:628-33.
28. 28 Ten Hove T, van Deventer SJH. Anti-TNF antibody Ca2 induces apoptosis in CD3/CD28 stimulated Jurkat cells: a; potent immunomodulatory mechnism. Gastroenterology 1999;116:A739.
29. 29 Lalani I, Bhol K, Ahmed AR. Interleukin-10. Biology, Role Inflammation Autoimmunity Annals of Allergy, Asthma and Immunology 1997;79:469-83.
30. 30 Leach MW, Davidson NJ, Fort MM, Powrie F, Rennick DM. The role of IL-10 in inflammatory bowel disease: 'of mice and men' [Review]. Toxicologic Pathol 1999;27:123-33.
31. 31 Rennick D, Davidson N, Berg D. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin Immunol Immunopathology 1995;76:S174-8.
32. 32 Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-42.
33. 33 Hagenbaugh A, Sharma S, Dubinett SM et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Medicine 1997; 185:2101-10.
34. 34 Huhn RD, Radwanski E, O'Connell SM et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996;87: 699-705.
35. 35 Fuchs AC, Granowitz EV, Shapiro L et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunology 1996;16:291-303.
36. 36 Pajkrt D, van der Poll T, Levi M et al. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 1997;89:2701-5.
37. 37 Huhn RD, Radwanski E, Gallo J et al. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Therapeutics 1997;62:171-80.
38. 38 van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Dis Study Group Gastroenterology 1997;113:383-9.
39. 39 Fedorak RN, Gangl A, Elson CO et al. Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's Dis Gastroenterol 1998;114:A974,G3993.
40. 40 Tilg H, KaSeries A, Propst A et al. Recombinant Human Interleukin-10 (rHuIL-10) therapy in steroid-refractory chronic active Crohn's disease (CACD): induction of neopterin, a degradation product of the pteridine pathway regulated by Interferon-gamma. Gastroenterology 1998;114:A1100.
41. 41 van Montfrans C, van de Ende A, Fedorak RN et al. Anti-and proinflammatory effects of interleukin-10 in mild to moderate Crohn's disease. Gastroenterology 1999;116:A777.
42. 42 Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Investigation 1998; 102:322-8.
43. 43 Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments]. New England J Med 1999;340:253-9.